Login or sign up
For business

NovaGo Therapeutics

4.0· 10 reviews
Average ratingGreat
4.0/ 5

Based on 10 reviews

530%
440%
330%
20%
10%
Ask AI

Questions about NovaGo Therapeutics

Based on 10 reviews, listing data and website checks · updated 7 days ago

What is NovaGo Therapeutics?

NovaGo Therapeutics is a Swiss clinical-stage biotech company founded in 2015 as a spin-off from the University of Zurich. The company develops human antibody therapeutics targeting cerebral stroke and spinal cord injury to stimulate nerve repair and regeneration. Their lead program targets Nogo-A, a potent inhibitor of nerve-fiber growth, to enhance functional recovery following spinal cord injury.

Where is NovaGo Therapeutics based and what does the location imply for visitors?

The company is located at Wagistrasse 27, 8952 Schlieren, Switzerland, which places it in the Zurich-Schlieren area. This location serves as the operational base for their team translating decades of Nogo-A research into therapies for the central nervous system.

How long has NovaGo Therapeutics existed and how has it evolved?

NovaGo Therapeutics has been in operation since its founding in 2015. The company has evolved from a pre-clinical research phase to a clinical-stage company with its first asset, the NG004 lead anti-Nogo-A antibody.

Who are the key people leading NovaGo Therapeutics?

The company's management team includes CEO Stefan Moese, Founder and Chief Scientific Officer Martin E. Schwab, CFO Roger Wetli, and board members Dominik Escher, Roger M. Nitsch, and Jan Grimm. This structure reflects a transition from pre-clinical research toward clinical development and partnerships.

What technology platform and partnerships does NovaGo Therapeutics use?

NovaGo Therapeutics collaborates with Neurimmune on the development of human therapeutic antibodies using their Reverse Translational Medicine™ (RTM™) technology platform. This partnership provides access to a unique class of human-derived antibodies with exceptional therapeutic properties.

What is the status of NovaGo Therapeutics' lead program?

The company's lead candidate, NG004, is currently in a Phase 1b clinical trial for acute spinal cord injury. This trial is part of the SPROUT Phase 1b study which began dosing in 2025.

What recent financing news is associated with NovaGo Therapeutics?

NovaGo Therapeutics secured a USD 30 million Series B financing round in August 2026. The round was led by Neurimmune and Pureos Bioventures, with participation from additional investors including Wings for Life and the Swiss Paraplegic Foundation.

What earlier financing rounds did NovaGo Therapeutics complete?

NovaGo Therapeutics received a CHF 10 million (USD 11 million) Series A financing round in 2019, led by Pureos Bioventures and Neurimmune. This funding supported their transition from pre-clinical research toward clinical development.

What is the Trustburn rating and review history for NovaGo Therapeutics?

NovaGo Therapeutics has a Trustburn rating of 4 out of 5 from 10 reviews. The most recent reviews date back to October 2023, showing a consistent pattern of positive feedback over time.

What do reviewers say about NovaGo Therapeutics?

Reviewers consistently praise NovaGo Therapeutics for their efficiency, professionalism, and knowledgeable team. Many customers highlight the excellent support, guidance, and top-notch products delivered on time.

How do customers describe their experience with NovaGo Therapeutics?

NovaGo Therapeutics is instrumental in helping customers achieve their goals, with products described as top-quality and customer service rated as unmatched. The team is noted for going above and beyond to ensure client satisfaction.

What specific benefits do customers report from NovaGo Therapeutics?

NovaGo Therapeutics has been a game-changer for many customers, helping them immensely with their products. The company is often described as simply the best, with services that have transformed lives.

What is the origin story of NovaGo Therapeutics?

NovaGo Therapeutics is a spin-off from the University of Zurich, initiated by Prof. Martin Schwab. The company was established to translate fundamental discoveries about Nogo-A into clinical-stage antibody programmes.

What specific medical conditions does NovaGo Therapeutics target?

NovaGo Therapeutics focuses on treating spinal cord injury and subacute ischemic stroke. Their approach involves temporarily blocking Nogo-A to re-open a window for repair after injury in the brain and spinal cord.

How can I contact NovaGo Therapeutics?

You can reach NovaGo Therapeutics by e-mail at info@novagotherapeutics.com.

AI-generated from reviews on this page. Verify anything important with the company directly.

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website — a simple way to convert your visitors into customers.

Get the widget for your site →

About NovaGo Therapeutics

NovaGo Therapeutics is a biotech start-up company dedicated to the development of human antibody therapeutics targeting cerebral stroke and spinal cord injury to stimulate nerve repair and regeneration. A strategic partnership with Neurimmune provides access to a unique class of human-derived antibodies with exceptional therapeutic properties generated through their Reverse Translational Medicine™ (RTM™) technology platform.